Using cross-species vaccination approaches to counter emerging infectious diseases
© 2021. Springer Nature Limited..
Since the initial use of vaccination in the eighteenth century, our understanding of human and animal immunology has greatly advanced and a wide range of vaccine technologies and delivery systems have been developed. The COVID-19 pandemic response leveraged these innovations to enable rapid development of candidate vaccines within weeks of the viral genetic sequence being made available. The development of vaccines to tackle emerging infectious diseases is a priority for the World Health Organization and other global entities. More than 70% of emerging infectious diseases are acquired from animals, with some causing illness and death in both humans and the respective animal host. Yet the study of critical host-pathogen interactions and the underlying immune mechanisms to inform the development of vaccines for their control is traditionally done in medical and veterinary immunology 'silos'. In this Perspective, we highlight a 'One Health vaccinology' approach and discuss some key areas of synergy in human and veterinary vaccinology that could be exploited to accelerate the development of effective vaccines against these shared health threats.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
Nature reviews. Immunology - 21(2021), 12 vom: 16. Dez., Seite 815-822 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Warimwe, George M [VerfasserIn] |
---|
Links: |
---|
Themen: |
Journal Article |
---|
Anmerkungen: |
Date Completed 14.12.2021 Date Revised 04.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41577-021-00567-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM326882014 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM326882014 | ||
003 | DE-627 | ||
005 | 20240404232444.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41577-021-00567-2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1364.xml |
035 | |a (DE-627)NLM326882014 | ||
035 | |a (NLM)34140665 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Warimwe, George M |e verfasserin |4 aut | |
245 | 1 | 0 | |a Using cross-species vaccination approaches to counter emerging infectious diseases |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.12.2021 | ||
500 | |a Date Revised 04.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. Springer Nature Limited. | ||
520 | |a Since the initial use of vaccination in the eighteenth century, our understanding of human and animal immunology has greatly advanced and a wide range of vaccine technologies and delivery systems have been developed. The COVID-19 pandemic response leveraged these innovations to enable rapid development of candidate vaccines within weeks of the viral genetic sequence being made available. The development of vaccines to tackle emerging infectious diseases is a priority for the World Health Organization and other global entities. More than 70% of emerging infectious diseases are acquired from animals, with some causing illness and death in both humans and the respective animal host. Yet the study of critical host-pathogen interactions and the underlying immune mechanisms to inform the development of vaccines for their control is traditionally done in medical and veterinary immunology 'silos'. In this Perspective, we highlight a 'One Health vaccinology' approach and discuss some key areas of synergy in human and veterinary vaccinology that could be exploited to accelerate the development of effective vaccines against these shared health threats | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 7 | |a Vaccines |2 NLM | |
700 | 1 | |a Francis, Michael J |e verfasserin |4 aut | |
700 | 1 | |a Bowden, Thomas A |e verfasserin |4 aut | |
700 | 1 | |a Thumbi, Samuel M |e verfasserin |4 aut | |
700 | 1 | |a Charleston, Bryan |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature reviews. Immunology |d 2001 |g 21(2021), 12 vom: 16. Dez., Seite 815-822 |w (DE-627)NLM117889695 |x 1474-1741 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2021 |g number:12 |g day:16 |g month:12 |g pages:815-822 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41577-021-00567-2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2021 |e 12 |b 16 |c 12 |h 815-822 |